New filtration technologies for antibody removal from donated blood components (SANGUIS)

用于从捐赠的血液成分中去除抗体的新型过滤技术 (SANGUIS)

• 批准号: 101218
• 金额: $ 50.56万
• 依托单位: NONWOVENS INNOVATION & RESEARCH INSTITUTE LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101218
• 关键词: New; filtration; technologies; antibody; removal

The feasibility of developing a new blood filter incorporating novel 'Hydrospace' textile technology containing pre-encapsulated binders for the selective removal of harmful antibodies in donated blood plasma has been proven in a 2011 TSB-funded feasability study. This project will further develop a robust, high quality, NHS-approved filter which is effective at removing sufficient levels of blood group specific antibodies. This will enable the production of universal plasma, enabling one plasma product to be transfused to patients of all blood groups, whilst maintaining the post-filtration blood component clinical quality. A universal plasma will result in clinical and economic benefits. Once developed, we intend that the blood pack manufacturing partner will gain Marketing Authorisation Approval and commercialise the filter.

2011年TSB资助的一项可行性研究证明，开发一种新型血液过滤器的可行性，该过滤器采用了新型“Hydrospace”纺织技术，含有预包封粘合剂，可选择性去除捐献血浆中的有害抗体。该项目将进一步开发一种耐用、高质量、经NHS批准的过滤器，可有效去除足够水平的血型特异性抗体。这将能够生产通用血浆，使一种血浆产品能够输注给所有血型的患者，同时保持过滤后血液成分的临床质量。通用血浆将产生临床和经济效益。一旦开发完成，我们希望血袋制造合作伙伴将获得上市许可批准并将过滤器商业化。